Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
Find out how Simcere and Stanford Medicine’s IPF collaboration could reshape early-stage antifibrotic drug discovery.
Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.
Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Avalyn Pharma moves AP02 into Phase 2, exploring whether nebulized delivery can improve risk benefit balance in IPF
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Why Baseimmune’s IPF entry challenges a decade of single-target failure in pulmonary fibrosis
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with […]